{
  "id": "63f03c47f36125a42600001e",
  "type": "factoid",
  "question": "ZF2001 is used for which disease?",
  "ideal_answer": "ZF2001 is used for COVID-19.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/35617368",
    "http://www.ncbi.nlm.nih.gov/pubmed/35568034",
    "http://www.ncbi.nlm.nih.gov/pubmed/35634276",
    "http://www.ncbi.nlm.nih.gov/pubmed/35596222"
  ],
  "snippets": [
    {
      "text": "Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35617368",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We assessed the safety and immunogenicity of heterologous immunization with a recombinant adenovirus type-5-vectored Coronavirus Disease 2019 (COVID-19) vaccine (Convidecia, hereafter referred to as CV) and a protein-subunit-based COVID-19 vaccine (ZF2001, hereafter referred to as ZF).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35617368",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Heterologous boosting with ZF2001 following primary vaccination with Convidecia is more immunogenic than a single dose of Convidecia and is not associated with safety concerns. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35617368",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusion: SARS-CoV-2 vaccines (CoronaVac, BBIBP-CorV, and ZF2001) are safe in thyroid cancer patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35634276",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effective protection of ZF2001 against the SARS-CoV-2 Delta variant in lethal K18-hACE2 mice.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35596222",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "To investigate the protective efficacy and mechanism of ZF2001 (a protein subunit vaccine with conditional approval in China) to SARS-CoV-2 Delta variant-induced severe pneumonia, the lethal challenge model of K18-hACE2 transgenic mice was used in this study. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35596222",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Previously, we developed the protein subunit vaccine ZF2001 based on the dimeric receptor-binding domain (RBD) of prototype SARS-CoV-2. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35568034",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "COVID-19"
}